Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Economic Impact of Antimicrobial Resistance
John E. McGowan
Table 4
Elements of the economic impact of measures to deal with antimicrobial drug resistance, by perspective affected
| Element | Measurementa | Perspective affected directly |
|---|---|---|
| Develop new antimicrobial agents | Costs associated with drug development - Profit resulting from new drug's use | Drug industry, HCB, patient, society |
| Conduct surveillance | Cost of surveillance for infected and colonized patients (R) - Cost of surveillance for infected and colonized patients (S) | HCB |
| Implement isolation | Costs associated with barrier isolation (R) - Costs associated with barrier isolation (S) | HCW, visitor, patient, HCB |
| Adapt lab procedures | Costs associated with testing (R) - Costs associated with testing (S) | HCB, patient, society |
| Educate about resistance | Costs associated with educational programs (staff, patients) (R) -Costs associated with educational programs (staff, patients) (S) | HCW, patient, visitor, HCB |
| Improve drug administration | Costs for programs to improve drug administration (R) - Costs for programs to improve drug administration (S) | HCW, HCB |
| Improve drug choice | Costs for programs to improve drug choice (R) - Costs for programs to improve drug choice (S) | Prescribers, HCB |
aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business; HCW = health-care workers.
Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."
Page created: May 10, 2011
Page updated: May 10, 2011
Page reviewed: May 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.